Ryska, Ales
Sapino, Anna
Landolfi, Stefania
Valero, Irene Sansano
Cajal, Santiago Ramon y
Oliveira, Pedro
Detillo, Paolo
Lianas, Luca
Frexia, Francesca
Nicolosi, Pier Andrea
Monti, Tommaso
Bussolati, Benedetta
Marchiò, Caterina
Bussolati, Gianni http://orcid.org/0000-0003-2175-5069
Funding for this research was provided by:
Regione Piemonte (POR FESR 2014-2020)
Università degli Studi di Torino
Article History
Received: 29 May 2023
Revised: 9 October 2023
Accepted: 29 October 2023
First Online: 24 November 2023
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013), Good Clinical Practice (GCP) principles, international standard for performance evaluation study of in vitro diagnostic (IVD) medical devices ISO 20916 and the laws and regulations of the countries where the study took place. The protocol and all the study-related documents were approved by the local Ethical Committees (IRCCS Candiolo, Prot.269/2019, Italy; Comité de Éticade Investigación, Pr 422/2019, Spain; Manchester Cancer Research Centre Biobank, ref: 18/NW/009, UK) before the beginning of the trial. All patients signed an informed consent prior to their participation in the study.
: PD is an employee of Addax Biosciences. GB and BB are co-founder of Addax Biosciences.